[{"id":"0a2db8ff-cbd1-468b-a91f-239d3b97766f","acronym":"AMELI-01","url":"https://clinicaltrials.gov/study/NCT03190278","created_at":"2023-08-14T10:10:57.638Z","updated_at":"2024-07-02T16:35:20.952Z","phase":"Phase 1","brief_title":"Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT03190278 - AMELI-01","lead_sponsor":"Cellectis S.A.","biomarkers":" IL3RA","pipe":"","alterations":" ","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UCART123"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 06/19/2017","start_date":" 06/19/2017","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-05"},{"id":"c680c5d8-4f65-49d8-aa7d-65b4bcfd55e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04106076","created_at":"2023-03-04T19:03:31.381Z","updated_at":"2024-07-02T16:36:43.310Z","phase":"Phase 1","brief_title":"Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia","source_id_and_acronym":"NCT04106076","lead_sponsor":"Cellectis S.A.","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UCART123"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 12/05/2019","primary_completion_date":" 12/05/2019","study_txt":" Completion: 12/05/2019","study_completion_date":" 12/05/2019","last_update_posted":"2020-07-14"}]